Learning Tracks

This session will explore how advances in analytical science, regulatory policy, and risk-based development approaches are reshaping expectations for streamlined biosimilar development. Panelists will discuss the expanding role of analytical similarity as the cornerstone of biosimilar development and how front-loaded analytical programs can support more efficient regulatory pathways while maintaining scientific rigor and patient confidence.

The discussion will examine how enhanced understanding of critical quality attributes, orthogonal structural and functional characterization, platform technologies, and modern statistical approaches can help mitigate residual uncertainty and inform development decisions, including when a comparative clinical efficacy study waiver may be scientifically appropriate. Panelists will also explore why such waivers are not automatic and must be supported by a robust, science- and risk-based framework grounded in high-quality analytics and, where needed, tailored clinical data.

Additional topics may include lessons learned from recent regulatory experience, reference product variability, strategies for addressing analytical differences, immunogenicity considerations, technical and manufacturing challenges, the potential role of in silico and in vitro approaches, and special considerations for locally acting or high-concentration products. The session will also examine how evolving FDA and global regulatory expectations may continue shifting biosimilar development toward increasingly analytical- and data-driven paradigms.